MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Renal Impairment
Conditions
Renal Impairment
Trial Timeline
Jun 13, 2024 → Sep 4, 2025
NCT ID
NCT06496217About MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109 is a phase 1 stage product being developed by MBX Biosciences for Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT06496217. Target conditions include Renal Impairment.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06496217 | Phase 1 | Completed |
Competing Products
20 competing products in Renal Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3473329 | Eli Lilly | Phase 1 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| Drotrecogin alfa activated (Xigris) | Eli Lilly | Phase 2 | 52 |
| LY3819469 | Eli Lilly | Phase 1 | 33 |
| Atezolizumab + Cabozantinib | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | 33 |
| DS-1093a | Daiichi Sankyo | Phase 1 | 33 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| AGS-16C3F | Astellas Pharma | Phase 1 | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | 33 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| YM178 | Astellas Pharma | Phase 1 | 33 |
| intravenous immunoglobulins (IVIG) | Astellas Pharma | Phase 1 | 33 |
| bixalomer | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |